Monday, April 30, 2012
it is all about your choice
you choose to move forward or stop and take responsibility for your choice
Thursday, April 19, 2012
The 25 Most Beautiful Public Libraries in the World
http://flavorwire.com/280318/the-25-most-beautiful-public-libraries-in-the-world#25
The 20 Most Beautiful Bookstores in the World
http://flavorwire.com/254434/the-20-most-beautiful-bookstores-in-the-world
Wednesday, April 18, 2012
white vs chinese
Vorauer, J. D., & Sakamoto, Y. (2006). I thought we could be friends, but . . . : Systematic miscommunication and defensive distancing as obstacles to cross-group friendship formation.
Psychological Science, 17, 326–331.
Psychological Science, 17, 326–331.
Tuesday, April 17, 2012
World Stem Cells, LLC. President Dr. Alan A. Kadish Gives Lecture at the 4th International Congress
http://www.free-press-release-center.info/pr00000000000000209992_world-stem-cells-llc-president-dr-alan-a-kadish-gives-lecture-at-the-4th-international-congress.html
Reaction breeds sorrow
So action which is born of reaction breeds sorrow. Most of our thoughts are the result of the past, of time. A mind that is not built on the past, that has totally understood this whole process of reaction, can act every minute totally, completely, wholly.Please do listen. What I am going to say will probably be rather difficult. So, listen as though you are far away. I am going to talk about something which you will come to, if you have gone through all this sweetly, with pleasure. When you have gone through the whole process of action born of reaction, and denied it with enchantment, with joy -not with pain- then you will see that you will come naturally, easily, to a state of mind that is the very essence of beauty. - Collected Works, Vol. XIII,143,Action
A truth is not perceived through any volition
Is it possible to understand anything without effort? Is it possible to see what is real, what is true, without introducing the action of will? - which is essentially based on the self, the 'me'. And if we do not make an effort, is there not a danger of deterioration, of going to sleep, of stagnation? Perhaps this evening, as I am talking, we can experiment with this individually, and see how far we can go through this question. For I feel the thing that brings happiness, quietness, tranquillity of the mind, does not come through any effort. A truth is not perceived through any volition, through any action of will. And if we can go into it very carefully and diligently, perhaps we shall find the answer. - Collected Works, Vol. VI,354,Action
Monday, April 16, 2012
New Moral Problems and New Approaches: Millennials Compared to Baby Boomers and Generation X
http://www.thesustainabilityreview.org/2012/04/new-moral-problems-and-new-approaches-millennials-compared-to-baby-boomers-and-generation-x/
Thursday, April 12, 2012
Wednesday, April 11, 2012
Researchers at the University of Bonn convert skin and umbilical cord cells directly into nerve cells
Researchers at the University of Bonn convert skin and umbilical cord cells directly into nerve cells
http://www.eurekalert.org/pub_
Until recently, the production of pluripotent "multipurpose" stem cells from skin cells was considered to be the ultimate new development. In the meantime, it has become possible to directly convert cells of the body into one another – without the time-consuming detour via a pluripotent intermediate stage. However, this method has so far been rather inefficient. Scientists from the Bonn Institute of Reconstructive Neurobiology (director: Prof. Dr. Oliver Brüstle) have now developed the method to the point that it can be used for biomedical applications. The scientists are presenting their results in the journal "Nature Methods".
There was much excitement surrounding cell reprogramming with the breakthrough of Shinya Yamanaka. In 2006, the Japanese scientist was able to reprogram skin cells for the first time with the aid of a few control factors into so-called induced pluripotent stem cells (iPS cells) – "multipurpose" cells from which all body cells can in principle be produced. In 2010, Marius Wernig, a former postdoctoral researcher with Prof. Brüstle and meanwhile the director of the institute at Stanford University in California, developed the idea further: Using only three so-called transcription factors, his team was able to perform direct transformation of skin cells into so-called induced neurons (iN). However, the method has so far been rather inefficient: Only a small percentage of the skin cells were converted into the desired nerve cells.
Researchers are increasing yields during transformation of cells
For the scientists at the LIFE & BRAIN Center at the University of Bonn, that was not enough. They are interested in the biomedical utilization of artificially produced human nerve cells for disease research, cell replacement, and the development of active substances. One concept seemed likely: Why not use low-molecular active substances - so-called small molecules - to optimize the process? Julia Ladewig, post-doctoral researcher and lead author of the study, began using such active substances to influence several signaling pathways important for cell development.
By blocking the so-called SMAD signaling pathway and inhibiting glycogen synthase kinase 3 beta (GSK3ß), they increased the transformational efficiency by several times – and were thus able to even simplify the means of extraction. Using only two instead of previously three transcription factors and three active substances, the Bonn researchers were able to convert a majority of the skin cells into neurons. In the end, their cell cultures contained up to more than 80% human neurons. And since the cells divide even further during the conversion process, the actual efficiency is even higher.
Two nerve cells are produced from one skin cell
"We can obtain up to more than 200,000 nerve cells converted in this way from 100,000 skin cells," says Julia Ladewig. In order to find the right combination of active substances, the Bonn scientists are focusing on signaling pathways which are especially important for cell specialization. "The SMAD signaling pathway and also GSK3ß were suspected of inhibiting the conversion of connective tissue cells and pluripotent stem cells into neural cells. The obvious step was to block both of them using corresponding active substances," says Philipp Koch, team leader and senior author responsible for the study, together with Prof. Brüstle. The results were intriguing: "We were able to demonstrate how the genes typical for skin fibroblast were gradually down-regulated and nerve-cell-specific genes were activated during the cell transformation. In addition, the nerve cells thus obtained were functionally active, which also makes them interesting as a source for cell replacement," says Ladewig.
Scientists are now transferring the method to other types of cells
The Bonn scientists have already transferred the method to other types of cells such as, for example, umbilical cord cells. Brüstle clearly foresees the next steps: "First of all, we want to use nerve cells obtained in this way for disease and active substance research. The long-term goal will be to convert cells directly in the body into nerve cells."
###
Ladewig, J., Mertens, J., Kesavan, J., Doerr, J., Poppe, D., Glaue, F., Herms, S., Wernet, P., Kögler, G., Müller, F.-J., Koch, P., Brüstle, O. (2012) Small molecules enable highly efficient neuronal conversion of human fibroblasts. Nature Methods (DOI: 10.1038/nmeth.1972)
http://www.eurekalert.org/pub_
Until recently, the production of pluripotent "multipurpose" stem cells from skin cells was considered to be the ultimate new development. In the meantime, it has become possible to directly convert cells of the body into one another – without the time-consuming detour via a pluripotent intermediate stage. However, this method has so far been rather inefficient. Scientists from the Bonn Institute of Reconstructive Neurobiology (director: Prof. Dr. Oliver Brüstle) have now developed the method to the point that it can be used for biomedical applications. The scientists are presenting their results in the journal "Nature Methods".
There was much excitement surrounding cell reprogramming with the breakthrough of Shinya Yamanaka. In 2006, the Japanese scientist was able to reprogram skin cells for the first time with the aid of a few control factors into so-called induced pluripotent stem cells (iPS cells) – "multipurpose" cells from which all body cells can in principle be produced. In 2010, Marius Wernig, a former postdoctoral researcher with Prof. Brüstle and meanwhile the director of the institute at Stanford University in California, developed the idea further: Using only three so-called transcription factors, his team was able to perform direct transformation of skin cells into so-called induced neurons (iN). However, the method has so far been rather inefficient: Only a small percentage of the skin cells were converted into the desired nerve cells.
Researchers are increasing yields during transformation of cells
For the scientists at the LIFE & BRAIN Center at the University of Bonn, that was not enough. They are interested in the biomedical utilization of artificially produced human nerve cells for disease research, cell replacement, and the development of active substances. One concept seemed likely: Why not use low-molecular active substances - so-called small molecules - to optimize the process? Julia Ladewig, post-doctoral researcher and lead author of the study, began using such active substances to influence several signaling pathways important for cell development.
By blocking the so-called SMAD signaling pathway and inhibiting glycogen synthase kinase 3 beta (GSK3ß), they increased the transformational efficiency by several times – and were thus able to even simplify the means of extraction. Using only two instead of previously three transcription factors and three active substances, the Bonn researchers were able to convert a majority of the skin cells into neurons. In the end, their cell cultures contained up to more than 80% human neurons. And since the cells divide even further during the conversion process, the actual efficiency is even higher.
Two nerve cells are produced from one skin cell
"We can obtain up to more than 200,000 nerve cells converted in this way from 100,000 skin cells," says Julia Ladewig. In order to find the right combination of active substances, the Bonn scientists are focusing on signaling pathways which are especially important for cell specialization. "The SMAD signaling pathway and also GSK3ß were suspected of inhibiting the conversion of connective tissue cells and pluripotent stem cells into neural cells. The obvious step was to block both of them using corresponding active substances," says Philipp Koch, team leader and senior author responsible for the study, together with Prof. Brüstle. The results were intriguing: "We were able to demonstrate how the genes typical for skin fibroblast were gradually down-regulated and nerve-cell-specific genes were activated during the cell transformation. In addition, the nerve cells thus obtained were functionally active, which also makes them interesting as a source for cell replacement," says Ladewig.
Scientists are now transferring the method to other types of cells
The Bonn scientists have already transferred the method to other types of cells such as, for example, umbilical cord cells. Brüstle clearly foresees the next steps: "First of all, we want to use nerve cells obtained in this way for disease and active substance research. The long-term goal will be to convert cells directly in the body into nerve cells."
###
Ladewig, J., Mertens, J., Kesavan, J., Doerr, J., Poppe, D., Glaue, F., Herms, S., Wernet, P., Kögler, G., Müller, F.-J., Koch, P., Brüstle, O. (2012) Small molecules enable highly efficient neuronal conversion of human fibroblasts. Nature Methods (DOI: 10.1038/nmeth.1972)
UCLA researcher explores the risk and rewards of stem cell products
UCLA researcher explores the risk and rewards of stem cell products
http://www.eurekalert.org/pub_
The brave new world of stem cell research dangles the exciting potential for a host of leading-edge treatments that may one day help cure debilitating diseases such as Alzheimer's and Parkinson's, maladies that today cannot be treated with modern medicine.
However, not much thought has been given to how those products might be regulated and how issues of legal liability may be addressed in a way that encourages scientific innovation but also protects the patients for whom these treatments might provide great relief.
Now, a lawyer from the UCLA School of Law and a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA has developed a road map that could help guide researchers, stem cell product manufacturers, treating physicians and patients through the complex maze of imagining, creating and developing stem cell products and using them to treat disease.
"Stem cell research and its eventual applications hold enormous promise, but they also carry some significant risks," said Stephen R. Munzer, a distinguished professor of law and author of the article. "Our understanding of the number and gravity of those risks right now is incomplete and uncertain. Developing a plan now that details how to deal with such issues as stem cell product liability is important, because we need to think carefully and rationally about how to address these issues before the market is flooded with products."
Munzer's work appears April 11, 2012 in the Boston University Journal of Science and Technology Law.
In the article, Munzer offers suggestions on how stem cell products might be classified in the future, examines how applying existing product liability rules to stem cell products is inadequate, details the economic considerations for a stem cell liability regime and offers his views of what the law should be on liability for stem cells.
"One thing I detect from the stem cell scientists I've spoken to is a certain amount of judicious caution," he said. "What they don't want is to have people rushing to get something approved by the FDA and then see it result in unanticipated, unforeseeable problems."
One of the byproducts of that judicious caution, both of risk of liability and potential risk to patients, Munzer said, has been scientists and biotech companies initially going after the so-called "low hanging fruit" of stem cell treatments, those projects that appear to have the least amount of risk and maximum benefit, such as treatments for retinal disease as opposed to organ regeneration.
In the article, Munzer also emphasizes the "ethics of risk," or having all those involved from the conception of an idea for a stem cell product to its eventual development and manufacture and administration, accountable for the risks they may be imposing on patients.
"The scientists who come up with the ideas for these products, the people who design them, the biotech companies that manufacture them and produce them in large numbers and the treating physicians who ultimately will be administering these treatments all have to be accountable, as well as the FDA, which is charged with regulating them," Munzer said.
Munzer likened the anticipation for potential stem cell products to the excitement created in the 1980s and 1990s over early gene therapies and what may have been a rush to test the therapies without adequately considering the risks. That potential for new treatments was temporarily derailed after an 18-year-old, Jesse Gelsinger, in a gene therapy trial died in 1999 as a result of the treatment.
"Existing blood products, growth factors, vaccines, we've got more understanding of how those things work and that is not true in the case of stem cells," Munzer said. "We want to create a strict liability regime that encourages innovation, but on the other hand does not encourage it so much that products are put on the market long before they should be."
Munzer suggests creating a social-insurance arrangement that would pool resources from everyone involved from the scientists to the manufacturers to the treating physician and the patients, contributing to a fund that could eventually be used to compensate those harmed by stem cell products during their testing. His proposal is similar to the National Vaccine Injury Compensation Program, a no fault alternative to the traditional tort system created in 1988 to ensure an adequate supply of vaccines, stabilize vaccine costs and establish and maintain an accessible and efficient forum for individuals found to be injured by certain vaccines.
Munzer also recommends limiting punitive damages in stem cells cases, but only if the product has been FDA approved and the FDA regulatory requirements have been strictly followed, the risks of the products have become more understood and predictable, and the FDA has gained sufficient experience in regulating the products.
Munzer's liability road map could be of value to courts, lawyers and regulatory bodies in navigating what is to come in stem cell product development. It also should be considered a dynamic document, he said, that responds to what is learned in the coming decades about the creation and development of stem cell products.
"It is important to address these issues this early with as much insight as we can bring to it, recognizing that there will be, as the years go on, more information and a better understanding of what we're doing," he said. "Starting to address this now instead of waiting five to 10 years is vital, as it will be much easier to prevent potential mishaps and messes from occurring than it will be to try to clean them up later."
Munzer's article attempts to tackle problems that are on or just beyond the horizon, and looks to what has happened in the past for guidance.
"The product liability claims regarding stem cell products will require the most exacting attention to their safety and effectiveness that is possible without imposing an undue burden on manufacturers," the study states. "No existing category offers a perfect legal model for stem cell products. However, we can tease out pertinent features of these categories for tort litigation to show what might work well for stem cell products. Definitive recommendations must wait for these products to appear on the market and for their risks and rewards to become better understood over the coming decades."
###
The stem cell center was launched in 2005 with a UCLA commitment of $20 million over five years. A $20 million gift from the Eli and Edythe Broad Foundation in 2007 resulted in the renaming of the center. With more than 200 members, the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research is committed to a multi-disciplinary, integrated collaboration of scientific, academic and medical disciplines for the purpose of understanding adult and human embryonic stem cells. The center supports innovation, excellence and the highest ethical standards focused on stem cell research with the intent of facilitating basic scientific inquiry directed towards future clinical applications to treat disease. The center is a collaboration of the David Geffen School of Medicine, UCLA's Jonsson Cancer Center, the Henry Samueli School of Engineering and Applied Science and the UCLA College of Letters and Science. To learn more about the center, visit our web site at http://www.stemcell.ucla.edu.
http://www.eurekalert.org/pub_
The brave new world of stem cell research dangles the exciting potential for a host of leading-edge treatments that may one day help cure debilitating diseases such as Alzheimer's and Parkinson's, maladies that today cannot be treated with modern medicine.
However, not much thought has been given to how those products might be regulated and how issues of legal liability may be addressed in a way that encourages scientific innovation but also protects the patients for whom these treatments might provide great relief.
Now, a lawyer from the UCLA School of Law and a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA has developed a road map that could help guide researchers, stem cell product manufacturers, treating physicians and patients through the complex maze of imagining, creating and developing stem cell products and using them to treat disease.
"Stem cell research and its eventual applications hold enormous promise, but they also carry some significant risks," said Stephen R. Munzer, a distinguished professor of law and author of the article. "Our understanding of the number and gravity of those risks right now is incomplete and uncertain. Developing a plan now that details how to deal with such issues as stem cell product liability is important, because we need to think carefully and rationally about how to address these issues before the market is flooded with products."
Munzer's work appears April 11, 2012 in the Boston University Journal of Science and Technology Law.
In the article, Munzer offers suggestions on how stem cell products might be classified in the future, examines how applying existing product liability rules to stem cell products is inadequate, details the economic considerations for a stem cell liability regime and offers his views of what the law should be on liability for stem cells.
"One thing I detect from the stem cell scientists I've spoken to is a certain amount of judicious caution," he said. "What they don't want is to have people rushing to get something approved by the FDA and then see it result in unanticipated, unforeseeable problems."
One of the byproducts of that judicious caution, both of risk of liability and potential risk to patients, Munzer said, has been scientists and biotech companies initially going after the so-called "low hanging fruit" of stem cell treatments, those projects that appear to have the least amount of risk and maximum benefit, such as treatments for retinal disease as opposed to organ regeneration.
In the article, Munzer also emphasizes the "ethics of risk," or having all those involved from the conception of an idea for a stem cell product to its eventual development and manufacture and administration, accountable for the risks they may be imposing on patients.
"The scientists who come up with the ideas for these products, the people who design them, the biotech companies that manufacture them and produce them in large numbers and the treating physicians who ultimately will be administering these treatments all have to be accountable, as well as the FDA, which is charged with regulating them," Munzer said.
Munzer likened the anticipation for potential stem cell products to the excitement created in the 1980s and 1990s over early gene therapies and what may have been a rush to test the therapies without adequately considering the risks. That potential for new treatments was temporarily derailed after an 18-year-old, Jesse Gelsinger, in a gene therapy trial died in 1999 as a result of the treatment.
"Existing blood products, growth factors, vaccines, we've got more understanding of how those things work and that is not true in the case of stem cells," Munzer said. "We want to create a strict liability regime that encourages innovation, but on the other hand does not encourage it so much that products are put on the market long before they should be."
Munzer suggests creating a social-insurance arrangement that would pool resources from everyone involved from the scientists to the manufacturers to the treating physician and the patients, contributing to a fund that could eventually be used to compensate those harmed by stem cell products during their testing. His proposal is similar to the National Vaccine Injury Compensation Program, a no fault alternative to the traditional tort system created in 1988 to ensure an adequate supply of vaccines, stabilize vaccine costs and establish and maintain an accessible and efficient forum for individuals found to be injured by certain vaccines.
Munzer also recommends limiting punitive damages in stem cells cases, but only if the product has been FDA approved and the FDA regulatory requirements have been strictly followed, the risks of the products have become more understood and predictable, and the FDA has gained sufficient experience in regulating the products.
Munzer's liability road map could be of value to courts, lawyers and regulatory bodies in navigating what is to come in stem cell product development. It also should be considered a dynamic document, he said, that responds to what is learned in the coming decades about the creation and development of stem cell products.
"It is important to address these issues this early with as much insight as we can bring to it, recognizing that there will be, as the years go on, more information and a better understanding of what we're doing," he said. "Starting to address this now instead of waiting five to 10 years is vital, as it will be much easier to prevent potential mishaps and messes from occurring than it will be to try to clean them up later."
Munzer's article attempts to tackle problems that are on or just beyond the horizon, and looks to what has happened in the past for guidance.
"The product liability claims regarding stem cell products will require the most exacting attention to their safety and effectiveness that is possible without imposing an undue burden on manufacturers," the study states. "No existing category offers a perfect legal model for stem cell products. However, we can tease out pertinent features of these categories for tort litigation to show what might work well for stem cell products. Definitive recommendations must wait for these products to appear on the market and for their risks and rewards to become better understood over the coming decades."
###
The stem cell center was launched in 2005 with a UCLA commitment of $20 million over five years. A $20 million gift from the Eli and Edythe Broad Foundation in 2007 resulted in the renaming of the center. With more than 200 members, the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research is committed to a multi-disciplinary, integrated collaboration of scientific, academic and medical disciplines for the purpose of understanding adult and human embryonic stem cells. The center supports innovation, excellence and the highest ethical standards focused on stem cell research with the intent of facilitating basic scientific inquiry directed towards future clinical applications to treat disease. The center is a collaboration of the David Geffen School of Medicine, UCLA's Jonsson Cancer Center, the Henry Samueli School of Engineering and Applied Science and the UCLA College of Letters and Science. To learn more about the center, visit our web site at http://www.stemcell.ucla.edu.
Tuesday, April 10, 2012
Action without reaction
The idea, the concept, the pattern is born of our thinking, which in turn is based upon our conditioning. All our thinking, however noble, refined or subtle, is the outcome of our experience, of our knowledge. There is no thinking without the past. Our thought is merely the reaction of memory. And what I am talking about is action without reaction, which means living without thought as the reaction of memory. - Collected Works, Vol. XIII,233,Action
The idealist is not revolutionary
The idealist is the man with an idea, and it is he who is not revolutionary. Ideas divide, and separation is disintegration, it is not revolution at all. The man with an ideology is concerned with ideas, words, and not with direct action; he avoids direct action. An ideology is a hindrance to direct action. - Commentaries on Living, Series II
Monday, April 09, 2012
A Review of the Civil Service Grading and Pay System
http://www.cpmr.gov.ie/Documents/A%20Review%20of%20Civil%20Service%20Grading%20and%20Pay%20Scales.pdf
Sunday, April 08, 2012
Federal Government Job Search Resources
http://www.law.gwu.edu/Careers/currentstudents/Documents/Graduating%20Students/Spg09How_to_Find_Entry_Level_Government_Attorney_Jobs.pdf
Federal Government Job Search Resources
• GS Basic Pay Scale – chart of the basic federal government salary.
• GS Locality Pay Tables – charts reflecting government salary by GS grade and location.
• Summary Analysis of Legal Positions in the Federal Government – overview of legal positions and hiring trends for attorneys in the federal government.
• Projected Attorney Hires By Agency – summary chart at Page 24, agency by agency analysis thereafter.
• Best Places to Work in the Federal Government 2007 – survey of the best federal agencies to work for.
•
Makingthedifference.org – site to help applicants navigate the federal job search process – legal career info: http://www.makingthedifference.org/federalcareers/law.shtml
• Corporation for National and Community Service
Last
Federal Government Job Search Resources
• GS Basic Pay Scale – chart of the basic federal government salary.
• GS Locality Pay Tables – charts reflecting government salary by GS grade and location.
• Summary Analysis of Legal Positions in the Federal Government – overview of legal positions and hiring trends for attorneys in the federal government.
• Projected Attorney Hires By Agency – summary chart at Page 24, agency by agency analysis thereafter.
• Best Places to Work in the Federal Government 2007 – survey of the best federal agencies to work for.
•
Makingthedifference.org – site to help applicants navigate the federal job search process – legal career info: http://www.makingthedifference.org/federalcareers/law.shtml
• Corporation for National and Community Service
Last
Position Classification Standard for General Attorney Series, GS-0905
http://www.opm.gov/fedclass/gs0905.pdf
Thursday, April 05, 2012
United States Government Policy and Supporting Positions Book
http://www.gpoaccess.gov/plumbook/2008/2008_plum_book.pdf -
This publication, commonly referred to as the Plum Book, is produced every four years, just after the presidential election. The Plum Book contains data (as of September 1, 2008) on over 7,000 Federal jobs that are political appointee positions. If you find a position that interests you, apply directly through that agency.
This publication, commonly referred to as the Plum Book, is produced every four years, just after the presidential election. The Plum Book contains data (as of September 1, 2008) on over 7,000 Federal jobs that are political appointee positions. If you find a position that interests you, apply directly through that agency.
fedscope
http://www.opm.gov/feddata/index.asp
http://www.fedscope.opm.gov/cognos/cgi-bin/ppdscgi.exe?DC=Q&E=/FSe%20-%20Status/Employment%20-%20March%202011&LA=en&LO=en-us&BACK=/cognos/cgi-bin/ppdscgi.exe?toc=%2FFSe%20-%20Status&LA=en&LO=en-us.
http://www.fedscope.opm.gov/cognos/cgi-bin/ppdscgi.exe?DC=Q&E=/FSe%20-%20Status/Employment%20-%20March%202011&LA=en&LO=en-us&BACK=/cognos/cgi-bin/ppdscgi.exe?toc=%2FFSe%20-%20Status&LA=en&LO=en-us.
PSLawNet
PSLawNet is the online resource connecting public interest law job-seekers with job opportunities at all experience levels. I
http://www.pslawnet.org/federalgovernmentresources#Reasons_to_consider_federal_employment
http://www.pslawnet.org/federalgovernmentresources#Reasons_to_consider_federal_employment
ABA Proposed Guidance
http://www.americanbar.org/groups/government_public/resources/public_lawyer_participation_in_bar_activities.html
Pro Bono Project Development: A Deskbook for Government and Public Sector Lawyers
http://www.americanbar.org/groups/government_public/publications.html
http://www.americanbar.org/content/dam/aba/migrated/2011_build/government_public/gvtattylowresfnl.authcheckdam.pdf
http://www.americanbar.org/content/dam/aba/migrated/2011_build/government_public/gvtattylowresfnl.authcheckdam.pdf
2011-2012 Federal Legal Employment Opportunities Guide
http://www.pslawnet.org/uploads/2011-12__FLEOG.pdf
Wednesday, April 04, 2012
U.S. Universities Rush to Set Up Outposts Abroad
http://www.nytimes.com/2008/02/10/education/10global.html
Faculty Gives Yale a Dose of Dissent Over Singapore
http://www.nytimes.com/2012/04/05/education/singapore-partnership-creates-dissension-at-yale.html
Tuesday, April 03, 2012
data
http://gee.cla.gov.tw/index.php?page_id=31b3b31a1c2f8a370206f111127c0dbd
http://www.dgbas.gov.tw/ct.asp?xItem=13213&CtNode=3504&mp=1
http://www.dgbas.gov.tw/ct.asp?xItem=13213&CtNode=3504&mp=1
Monday, April 02, 2012
Public Sector Employment, Rent Seeking and Economic Growth
The Economic Journal
Vol. 101, No. 408 (Sep., 1991), pp. 1186-1199
Vol. 101, No. 408 (Sep., 1991), pp. 1186-1199
http://www.jstor.org/discover/
Listening is an action of truth
Please, since you have taken the trouble to come here, may I suggest that in listening to what I am saying, you listen to the end, and not just take little bits here and there which happen to suit you; listen to the totality of it, and you will see that the whole thing hangs together. If you take a little part of it, you will have only the ashes which will create more misery, more sorrow, more confusion.Also, listening itself is quite an art. Most of us never really listen, therefore we hear only partially. We hear the words that are spoken, but our minds are elsewhere; or our minds respond only to the meaning of the words, and this immediate response prevents us from hearing that which lies beyond the words. So listening is an art; but if you can listen totally to what is being said, then in that very listening you will find there is a liberation, because such listening is unpremeditated, uncalculated; it is an action of truth because your whole mind is there, your total attention is being given. If you listen without interpreting, without remembering a quotation from some old book, or comparing all this with what you have read, then you will find that your own mind has undergone a really radical change. - Collected Works, Vol. X,Action
International Social Innovation Research Conference
In September 2012 the 4th International Social Innovation Research Conference will be hosted at the University of Birmingham, UK. Confirmed speakers include Dennis Young (Georgia State University), Alex Nicholls (Oxford University), Graham Smith (University of Southampton), Pascal Dey (St Gallen University), Pete Alcock (University of Birmingham) and Roger Spear (the Open University). There are just four weeks remaining for you to submit abstracts.
4th INTERNATIONAL SOCIAL INNOVATION RESEARCH CONFERENCE (ISIRC)
Third Sector Research Centre, University of Birmingham
12-14 September 2012
Third Sector Research Centre, University of Birmingham
12-14 September 2012
Each year ISIRC brings together the international academic community focusing on social entrepreneurship, enterprise and innovation. Please see the conference website for more details:
Call for Papers and Panels
Abstract submissions for single papers should be no longer than one page or c. 500 words. Abstracts indicating the conference stream they should be considered for should be sent directly to the Conference Organiser, Simon Teasdale (ISIRC@tsrc.ac.uk )
Abstract submissions for panel sessions should include a 300 word proposal for a co-ordinated set of papers on a particular theme. Abstracts should identify and justify the panel theme, and a full abstract for each panel paper should also be included. Panel abstracts should be sent directly to the Conference Organiser, Simon Teasdale (ISIRC@tsrc.ac.uk).
Single paper and Panel Abstract submissions are required by April 20th 2012. Acceptance will be confirmed by May 21st 2012. Full papers are required by August 24th 2012. Full papers should be no longer than 9,000 words and should be sent directly to the conference organiser.
Selected papers will be eligible for publication in special issues of: The Journal of Social Entrepreneurship, International Journal of Public Sector Management and Social Enterprise Journal.
Conference Streams:
1. Starting and scaling up social ventures
2. Towards a critical understanding of social entrepreneurship
3. Impact and Performance
Abstract submissions for single papers should be no longer than one page or c. 500 words. Abstracts indicating the conference stream they should be considered for should be sent directly to the Conference Organiser, Simon Teasdale (ISIRC@tsrc.ac.uk )
Abstract submissions for panel sessions should include a 300 word proposal for a co-ordinated set of papers on a particular theme. Abstracts should identify and justify the panel theme, and a full abstract for each panel paper should also be included. Panel abstracts should be sent directly to the Conference Organiser, Simon Teasdale (ISIRC@tsrc.ac.uk).
Single paper and Panel Abstract submissions are required by April 20th 2012. Acceptance will be confirmed by May 21st 2012. Full papers are required by August 24th 2012. Full papers should be no longer than 9,000 words and should be sent directly to the conference organiser.
Selected papers will be eligible for publication in special issues of: The Journal of Social Entrepreneurship, International Journal of Public Sector Management and Social Enterprise Journal.
Conference Streams:
1. Starting and scaling up social ventures
2. Towards a critical understanding of social entrepreneurship
3. Impact and Performance
4. Public services and innovation
5. Governance and stakeholder relationships
6. The politics of social innovation
In partnership with
Saïd Business School, University of Oxford;
Andrew Young School of Policy Studies, Georgia State University;
Queensland University of Technology;
London South Bank University;
Co-operatives Research Unit, The Open University;
Institute for Business Ethics, University of St Gallen;
Liverpool Hope University;
Third Sector Research Centre and CEEDR, Middlesex University;
University of Northampton.
University of Sheffield Management School
WU Vienna University of Economics and Business
Goldsmiths, University of London
Emerald
Policy Press
Total action brings about right action
Without understanding comprehensively the full significance of action, merely to be concerned with a particular form of action seems to me very destructive. Surely, if we are concerned only with the part and not with the whole, then all action is destructive action. But if we can understand action as a total thing, if we can feel our way into it and capture its significance, then that understanding of total action will bring about right action in the particular. It is like looking at a tree; the tree is not just the leaf, the branch, the flower, the fruit, the trunk, or the root, it is a total thing. To feel the beauty of a tree is to be aware of its wholeness, the extraordinary shape of it, the depth of its shadow, the flutter of its leaves in the wind. Unless we have the feeling of the whole tree, merely looking at a single leaf will mean very little. But if we have the feeling of the whole tree, then every leaf, every twig has meaning, and we are sensitive to it. After all, to be sensitive to the beauty of something is to perceive the totality of it. The mind that is thinking in terms of a part can never perceive the whole. In the whole the part is contained, but the part will never make up the whole, the total. - Collected Works, Vol. XII,341,Action
Complete action brings intelligence
It seems to be one of the most difficult things in life to live completely totally - not fragmentarily but as a total human being - whether you are in your office or in your home, or whether you are walking in a wood. It is only complete action that brings about intelligence: total action is intelligence. But we live in fragments: as a family man opposed to the rest of the world, as a religious man - if one is at all religious - having peculiar theories, ideas, separate beliefs and dogmas. And one is always struggling to achieve a status, a position, a prestige, whether that status is worldly or saintly. One is always striving, striving. There is never a moment when the mind is completely empty and therefore silent. And out of silence action takes place. We are no longer original. We are the result, a!s we have said over and over again, of our environments, of circumstances, of the culture, the tradition in which we live, and we accept that. And to change always demands a great deal of energy. - Collected Works, Vol. XVII,119,Action
Religion and Organization: A Critical Review of Current Trends and Future Directions
The Academy of Management Annals
Is it possible to act at all times without a purpose?
Questioner: For truth to come, you advocate action without idea. Is it possible to act at all times without idea, that is, without a purpose in view?
Krishnamurti: I am not advocating anything. I am not a propagandist, political or religious. I am not inviting you to any new experience. All that we are doing is trying to find out what action is. You are not following me to find out. If you do, then you will never find out. You are only following me verbally. But if you want to find out, if you as an individual want to find out what idea and action are, you have to inquire into it, and not accept my definition or my experience, which may be utterly false. As you have to find out, you have to put aside the whole idea of following, pursuing, advocating, propagandist, leader or example. Let us therefore find out together what we mean by action without idea. Please give your thought to it. Don't say, 'I do not understand what you are talking about.' Let us find out together. It may be difficult, but let us go into it. - Collected Works, Vol. VI, Action
We escape from action through ideology
There cannot be a world transformation, a revolution, as long as action is based on ideas; because action then is merely reaction; therefore ideas become much more important than action, and that is precisely what is taking place in the world, isn't it? To act, we must discover the impediments that prevent action. But most of us don't want to act, that is our difficulty. We prefer to discuss, we prefer to substitute one ideology for another, and so we escape from action through ideology. - Collected Works, Vol. VI,54,Action
When one gives one s heart, it is a total action
When one gives one's heart, it is a total action. And when you give your mind, it is a fragmentary action. And most of us give our minds to so many things. That is why we live a fragmentary life, thinking one thing and doing another; and we are torn, contradictory. To understand something, one must give not only one's mind but one's heart to it. - Collected Works, Vol. XV,6,Action
Sunday, April 01, 2012
Journal of Organizational Change Management
http://www.emeraldinsight.com/products/journals/author_guidelines.htm?id=jocm
Subscribe to:
Posts (Atom)
